SCYNEXIS, Inc.

NasdaqCM:SCYX Stock Report

Market Cap: US$26.7m

SCYNEXIS Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

David Angulo

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage29.36%
CEO tenure3yrs
CEO ownership0.9%
Management average tenure3.3yrs
Board average tenure10.6yrs

Recent management updates

Recent updates

Can SCYNEXIS (NASDAQ:SCYX) Afford To Invest In Growth?

Sep 09
Can SCYNEXIS (NASDAQ:SCYX) Afford To Invest In Growth?

Here's Why SCYNEXIS (NASDAQ:SCYX) Must Use Its Cash Wisely

May 17
Here's Why SCYNEXIS (NASDAQ:SCYX) Must Use Its Cash Wisely

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 08
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Apr 04
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Scynexis: Update Following Restructuring Of GSK Deal

Apr 02

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Feb 01
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Dec 21
Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26
Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07
SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13
Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03
Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

CEO Compensation Analysis

How has David Angulo's remuneration changed compared to SCYNEXIS's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$25m

Jun 30 2025n/an/a

-US$20m

Mar 31 2025n/an/a

-US$27m

Dec 31 2024US$2mUS$595k

-US$21m

Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

US$101m

Dec 31 2023US$1mUS$565k

US$67m

Sep 30 2023n/an/a

US$72m

Jun 30 2023n/an/a

US$44m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$1mUS$482k

-US$63m

Sep 30 2022n/an/a

-US$78m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$987kUS$461k

-US$33m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$45m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$939kUS$447k

-US$55m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$38m

Dec 31 2019US$1mUS$437k

-US$54m

Compensation vs Market: David's total compensation ($USD2.03M) is above average for companies of similar size in the US market ($USD578.00K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Angulo (60 yo)

3yrs
Tenure
US$2,027,854
Compensation

Dr. David Gonzalez Angulo, M. D., had been the Chief Medical Officer at SCYNEXIS, Inc. since June 1, 2015. He is President, Director and Chief Executive Officer of SCYNEXIS, Inc. from January 1, 2023. Dr....

Leadership Team

NamePositionTenureCompensationOwnership
David Angulo
CEO, President & Director3yrsUS$2.03m0.86%
$ 229.2k
Ivor Macleod
Chief Financial Officer3.3yrsUS$1.19m0.17%
$ 45.5k
Scott Sukenick
Chief Legal Officer & Corporate Secretary8.2yrsUS$1.18m0.44%
$ 118.3k
Daniella Gigante
Vice President of Human Resources & Information Technologyno datano datano data
3.3yrs
Average Tenure
60yo
Average Age

Experienced Management: SCYX's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Angulo
CEO, President & Director3yrsUS$2.03m0.86%
$ 229.2k
Armando Anido
Independent Director7yrsUS$131.47k0.11%
$ 30.6k
David Hastings
Independent Director10.3yrsUS$138.97k0.11%
$ 29.4k
Ann Hanham
Independent Director17.1yrsUS$138.97k0.11%
$ 29.7k
Guy MacDonald
Independent Chairman of the Board11.2yrsUS$161.47k0.13%
$ 35.0k
Steven Gilman
Independent Director10.9yrsUS$138.97k0.11%
$ 29.9k
David Denning
Member of Scientific Advisory Boardno datano datano data
Peter Pappas
Member of Scientific Advisory Boardno datano datano data
Oliver Cornely
Member of Scientific Advisory Boardno datano datano data
Barbara Alexander
Member of Scientific Advisory Boardno datano datano data
Mahmoud Ghannoum
Member of Scientific Advisory Boardno datano datano data
Paul Nyirjesy
Member of Scientific Advisory Boardno datano datano data
10.6yrs
Average Tenure
66.5yo
Average Age

Experienced Board: SCYX's board of directors are seasoned and experienced ( 10.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 13:46
End of Day Share Price 2026/01/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SCYNEXIS, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian Kemp DolliverBrookline Capital Markets
Corey DavisCanaccord Genuity
Liisa BaykoCitizens JMP Securities, LLC